The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
Open accessAbstract
In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). One hundred sixty patients were randomly assigned 1:1:1 to receive sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator's choice (n = 54; crossover permitted after primary analysis). Overall survival (OS) analysis, a key secondary end point, although not adequately powered, was prespecified at 50% maturity (after approximately 80 deaths). In this study, we report the OS, updated overall response rates (ORRs), and data for safety. After a median follow-up of 13.6 months, 24, 28, and 30 deaths occurred in the sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator's choice arms, respectively; updated objective response rates (ORRs; 95% CI) were 30.2% (95% CI, 18.3 to 44.3), 7.5% (95% CI, 2.1 to 18.2), and 1.9% (95% CI, 0.0 to 9.9), respectively. Compared with investigator's choice, the hazard ratios (HRs [95% CI]) for OS were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) with sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) with sotorasib 240 mg-panitumumab. No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical trial CodeBreaK 300 phase III, which focused on KRAS G12C, showed that the combination of sotorasib and panitumumab significantly improved the progression-free survival (PFS) compared to standard chemotherapy [58].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The phase III CodeBreaK 300 trial demonstrated improved progression-free survival with the combination of sotorasib and panitumumab compared with standard treatment, supporting the concept of vertical pathway inhibition in KRAS G12C-mutated tumors [58].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“In CodeBreaK 300, sotorasib plus panitumumab improved PFS compared with investigator’s choice therapy in previously treated KRAS G12C-mutant metastatic CRC.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214963 · Cited by 467
Self-citationSotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Self-citationDasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00772-9 · Cited by 368
Self-citationYaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0217 · Cited by 139
van de Haar, J., Ma, X., Ooft, S., van der Helm, P. W., Hoes, L. R., Mainardi, S., Pinato, D. J., Sun, K., Salvatore, L., Tortora, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02240-8 · Cited by 94
Self-citationTabernero, J., Taieb, J., Fakih, M., Prager, G. W., Van Cutsem, E., Ciardiello, F., Mayer, R. J., Amellal, N., Skanji, D., Calleja, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102945 · Cited by 18
Self-citation
Cited by
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
“After a median follow-up of 13.6 months, objective response rates were 30.2%, 7.5%, and 1.9%, respectively, and median OS was not reached for the 960 mg arm, 11.9 months for the 240 mg arm, and 10.3 months for the investigator’s choice [126].”
InfluentialHenrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“The phase III CodeBreaK 300 trial demonstrated improved progression-free survival with the combination of sotorasib and panitumumab compared with standard treatment, supporting the concept of vertical pathway inhibition in KRAS G12C-mutated tumors [58].”
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
Metadata
- Authors
- Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K.-H., Chan, E., Chao, J., Tran, Q., Cremolini, C., & Fakih, M.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Università Cattolica del Sacro Cuore (IT)
- National Hospital Organization Kyushu Cancer Center (JP)
- Stiftung Charité (DE)
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Université Paris Cité, SIRIC CARPEM Comprehensive Cancer Center, Department of Gastroenterology and Digestive Oncology, Hopital Européen Georges Pompidou, Paris, France
- National and Kapodistrian University of Athens (GR)
- GI Oncology Department & Translational Medicine Laboratory, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico
- Asan Medical Center (KR)
- National Cancer Center Hospital East (JP)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Royal Marsden Hospital (GB)
- National Taiwan University (TW)
- Amgen (United States) (US)
- University of Pisa (IT)
- City Of Hope National Medical Center (US)
- Corresponding author
- Fakih, Marwan
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2025-07
- Volume
- 43
- Issue
- 19
- Pages
- 2147-2154
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC12199804
- OpenAlex
- W4409350464
- Cited by
- 51
- References
- 8
- Citations by year
- 2026: 39 · 2025: 12
- FWCI
- 20.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- sotorasib, panitumumab, KRAS G12C, metastatic colorectal cancer, overall survival, progression-free survival, objective response rate, trifluridine/tipiracil, regorafenib, EGFR inhibition, drug safety
- MeSH terms
- Panitumumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Phenylurea Compounds, Piperazines, Pyridines, Pyrimidines, Sulfonamides, Thymine, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. https://app.cochat.ai/papers/10.1200/jco-24-02026
- The paper
- Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K.-H., Chan, E., Chao, J., Tran, Q., Cremolini, C., & Fakih, M. (2025). Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.